HypoThermosol Utilized as Combination Biopreservation Medium and Vehicle Solution for Therapeutic Cells
BLFS' customer TiGenix NV (Euronext Brussels: TIG) has completed a PI clinical safety trial of its expanded adipose-derived stem cell platform incorporating BioLife's cGMP HypoThermosol cell/tissue storage/shipping medium.
The clinical trial, titled "PI Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs),"assessed the safety, tolerability and feasibility of a potential cell-based therapy TiGenix is developing for a number of autoimmune disorders including rheumatoid arthritis.
The Bottom Line: HypoThermosol allows TIG to increase the stability profile of its clinical cell-based products and extend their shelf-life … the key in the commercial distribution. I have continually … touted BLFS as a "BUY" opportunity. It has enjoyed its recent joys of growth spurts and its sorrow in profit taking by day trader and investors - a market made timing for traders. BLFS closed at $0.30 in a day's range of $0.30 to $0.30 with only 600 share volume. I continue to reiterate this as a "BUY" on <these> downdraft … still sticking to BLFS being under-valued -with a target of $0.50 by years end since the stock has already visited $0.45 on 11/23/12. I could foresee a $0.05 to $0.10 rise based on the thinly traded activity of the stock many times without a news stimulus.
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.